Rasat R, Espiner E A, Abbott G D
Christchurch Hospital.
N Z Med J. 1995 Aug 11;108(1005):311-4.
To assess outcome (final height and sexual maturation), growth patterns and blood pressure in 16 children with congenital adrenal hyperplasia treated at one institution over a 30 year period.
Growth patterns and maturation were determined by retrospective review (median follow up period 14 years). Dose adjustment of corticosteroid replacement treatment, sufficient to maintain normal levels of adrenal precursor secretion, was determined using assays of urinary pregnanetriol excretion (up to 1975) or early morning measurements of plasma 17 hydroxy progesterone and plasma renin activity at intervals of 4-6 months.
In 7 of 15 patients the growth pattern during infancy was retarded--13 not exceeding the population mean. Catchup growth as steroid dose fell with age was not usually observed. In boys, height potential was further compromised by a significant reduction in growth velocity during puberty. None of nine patients evaluated at final height had attained the target height. During the first year of life, plasma renin activity was suppressed below the reference range in six of nine infants. Despite this, and lower than normal levels of plasma renin activity in childhood, most children were normotensive.
Avoiding salt depletion in infancy and excessive androgen secretion during childhood do not ensure normal growth patterns or normal final height. Impaired final height in congenital adrenal hyperplasia is more likely to be due to over treatment, particularly in infancy when lower doses of corticosteroids may improve height prognosis.
评估在一家机构接受治疗30年的16例先天性肾上腺皮质增生症患儿的治疗结果(最终身高和性成熟情况)、生长模式及血压。
通过回顾性分析确定生长模式和成熟情况(中位随访期14年)。使用尿孕三醇排泄测定法(至1975年)或每隔4 - 6个月清晨测定血浆17 - 羟孕酮和血浆肾素活性,来确定足以维持肾上腺前体分泌正常水平的皮质类固醇替代治疗的剂量调整。
15例患者中有7例在婴儿期生长模式迟缓,13例未超过人群均值。通常未观察到随着年龄增长类固醇剂量下降时的追赶生长。在男孩中,青春期生长速度显著降低进一步损害了身高潜力。在评估最终身高的9例患者中,无一人达到目标身高。在生命的第一年,9例婴儿中有6例血浆肾素活性被抑制至参考范围以下。尽管如此,且儿童期血浆肾素活性低于正常水平,但大多数儿童血压正常。
在婴儿期避免盐耗竭以及在儿童期避免雄激素分泌过多并不能确保正常的生长模式或正常的最终身高。先天性肾上腺皮质增生症最终身高受损更可能是由于治疗过度,尤其是在婴儿期,此时较低剂量的皮质类固醇可能改善身高预后。